Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 5
Abstract
Physiologically based absorption models can be an important tool in understanding product performance and hence implementation of Quality by Design (QbD) in drug product development. In this report, we show several case studies to demonstrate the potential application of absorption modeling in rational design of drug product under the QbD paradigm. The examples include application of absorption modeling—(1) prior to first-in-human studies to guide development of a formulation with minimal sensitivity to higher gastric pH and hence reduced interaction when co-administered with PPIs and/or H2RAs, (2) design of a controlled release formulation with optimal release rate to meet trough plasma concentrations and enable QD dosing, (3) understanding the impact of API particle size distribution on tablet bioavailability and guide formulation design in late-stage development, (4) assess impact of API phase change on product performance to guide specification setting, and (5) investigate the effect of dissolution rate changes on formulation bioperformance and enable appropriate specification setting. These case studies are meant to highlight the utility of physiologically based absorption modeling in gaining a thorough understanding of the product performance and the critical factors impacting performance to drive design of a robust drug product that would deliver the optimal benefit to the patients.
Authors and Affiliations
Filippos Kesisoglou, Amitava Mitra
Keywords
Related Articles
- EP ID EP681004
- DOI 10.1208/s12248-015-9781-1
- Views 67
- Downloads 0
k Opioids as potential treatments for stimulant dependence
Stimulant abuse is a major problem in the United States and the development of pharmacological treatments for stimulant abuse remains an important therapeutic goal. Classically, the “dopamine hypothesis”...
Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse
Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with...
CNS drug delivery: Opioid peptides and the blood-brain barrier
Peptides are key regulators in cellular and intercellular physiological responses and possess enormous promise for the treatment of pathological conditions. Opioid peptide activity within the central nervous system (CNS)...
Repeat Analysis and Incurred Sample Reanalysis: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team
The A7 harmonization team (A7 HT), a part of the Global Bioanalysis Consortium (GBC), focused on reviewing best practices for repeat analysis and incurred sample reanalysis (ISR) as applied during regulated bioanalysis....
Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans
The online version of this article (doi:10.1208/s12248-014-9636-1) contains supplementary material, which is available to authorized users.